Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-2910 for prevention of paclitaxel-induced peripheral neuropathy in breast cancer
jRCT2031230173Phase 2Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chemotherapy-induced peripheral neuropathy (CIPN) comparing ONO-2910 + weekly paclitaxel with Placebo + weekly paclitaxel (2 arms). Primary endpoints: Proportion of subjects with Grade 2 or higher peripheral sensory neuropathy by 12 weeks after starting administration and Safety and tolerability. Started Aug 2023; status: completed.
02
Drugs
ONO-2910
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on jRCT2031230173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230173.